title: Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
abstract: Golimumab is an anti-TNF monoclonal antibody administred subcutaneously once a month and produced with an innovative technology that minimizes immunogenicity. This paper reviews and updates the main studies on the efficacy, safety and pharmacoeconomic aspects of treatment with golimumab of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.
authors.affiliation: Rheumatology Unit, University of Verona. maurizio.rossini@univr.it.
authors.forename: M
authors.initials: M
authors.lastname: Rossini
authors.forename: O
authors.initials: O
authors.lastname: Viapiana
authors.forename: G
authors.initials: G
authors.lastname: Orsolini
authors.forename: E
authors.initials: E
authors.lastname: Fracassi
authors.forename: L
authors.initials: L
authors.lastname: Idolazzi
authors.forename: D
authors.initials: D
authors.lastname: Gatti
authors.forename: S
authors.initials: S
authors.lastname: Adami
authors.forename: M
authors.initials: M
authors.lastname: Govoni
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; C529000:golimumab